Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 2/20 | 0.49 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.49 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.49 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.49 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.49 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.49 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.49 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.49 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | CACNA1E | Q15878 | 2/20 | 0.49 |
| ▸ | CACNA2D4 | Q7Z3S7 | 2/20 | 0.49 |
| ▸ | CACNA2D3 | Q8IZS8 | 2/20 | 0.49 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12138360 | 0.94 | PIK3CD (0.47) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL3716533 | 0.90 | CACNB4 (0.54) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL3709887 | 0.89 | GPR119 (0.48) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL3708948 | 0.89 | GPR119 (0.51) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL3055131 | 0.88 | GPR119 (0.47) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL3805418 | 0.86 | KDM1A (0.53) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL3711289 | 0.86 | HRH1 (0.52) | PDE4APDE4BPDE4CPDE4DHRH1 | |
| SCHEMBL3715445 | 0.84 | HRH1 (0.48) | GPR119PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3718500 | 0.84 | HRH1 (0.52) | HRH1KCNH2 | |
| SCHEMBL3648875 | 0.83 | HRH1 (0.46) | GPR119HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| US-7884114-B2 | N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide for treatment of allergic rhinitis | GLAXO GROUP LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-2205585-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | Glaxo Group Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| EP-2185542-A2 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-20090270355-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| WO-2009050204-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009021965-A2 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270355-A1 | Compounds | CMA1, HRH4, CCL11 | CACNB4 3573/4885CACNA1A 2134/4885CACNA1G 3637/4885 |
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | IL5, HRH2, HRH1 | CACNB4 3853/4885CACNA1A 1108/4885CACNA1G 3222/4885 |
| US-20110281909-A1 | SUBSTITUTED QUINOLINE DERIVATIVES AS H1 RECEPTOR ANTAGONISTS | HRH1, HRH2, HRH4 | CACNB4 3090/4885CACNA1A 1027/4885CACNA1G 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.